Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned an average rating of “Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $107.00.

MNPR has been the topic of a number of recent analyst reports. Morgan Stanley started coverage on shares of Monopar Therapeutics in a research report on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research report on Thursday, January 29th. BTIG Research restated a “buy” rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a research note on Monday, February 23rd. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st.

Monopar Therapeutics Trading Down 1.8%

MNPR stock opened at $55.25 on Wednesday. The stock has a market cap of $369.07 million, a P/E ratio of -16.06 and a beta of 1.58. Monopar Therapeutics has a twelve month low of $26.06 and a twelve month high of $105.00. The company’s 50 day moving average is $60.48 and its two-hundred day moving average is $70.69.

Insider Activity

In other news, CFO Quan Anh Vu purchased 1,500 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the purchase, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at $104,925. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at approximately $673,000. Jane Street Group LLC purchased a new position in shares of Monopar Therapeutics during the first quarter worth approximately $377,000. Geode Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after acquiring an additional 48,379 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics in the 2nd quarter valued at $34,000. Finally, JPMorgan Chase & Co. raised its position in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.